Erythromycin lactobionate

Erythromycin lactobionate

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in an increase in the latter's blood concentration and toxic reactions. This product can inhibit the latter's metabolism and prolong its duration of action when used in combination with alfentanil. This product can increase cardiac toxicity when used in combination with antihistamines such as astemizole or terfenadine, and can increase the latter's blood concentration and produce nephrotoxicity when used in combination with cyclosporine. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and is not recommended for combined use. 3. This product is an antibacterial agent that can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid antiviral effect is required, such as the treatment of meningitis, the two should not be used together. 4. Patients who have been taking warfarin for a long time may experience a prolonged prothrombin time when using erythromycin, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used together, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the combination of this product with xanthines can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of co-use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthines should be adjusted during and after the combined treatment of the two. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, its metabolism can be inhibited and blood concentrations can be increased, which may cause rhabdomyolysis. When used in combination with midazolam or triazolam, the clearance of the two can be reduced and their effects can be enhanced.

The main ingredient of this product is azithromycin lactobionate. Its chemical name is (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one lactobionate. Molecular formula: C38H72N2O122C12H22O12 Molecular weight: 1465.59

1 When used in combination with theophylline, the latter's concentration in plasma can be increased, and attention should be paid to detecting plasma theophylline levels. 2 When used in combination with warfarin, attention should be paid to checking the prothrombin time. 3 When used simultaneously with the following drugs, it is recommended to closely observe the patient: Digoxin increases digoxin levels. Ergotamine or dihydroergotamine acute ergot toxicity, symptoms are severe peripheral vasospasm and dysesthesia (pain to touch). Triazolam enhances the pharmacological effects of triazolam by reducing its degradation. Cytochrome P450 system metabolites increase the levels of carbamazepine, terfenadine, cyclosporine, cyclohexylbarbital, and phenytoin in serum. 4 When used in combination with rifabutin, the latter's toxicity will be increased.

Erythromycin lactobionate

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in an increase in the latter's blood concentration and toxic reactions. This product can inhibit the latter's metabolism and prolong its duration of action when used in combination with alfentanil. This product can increase cardiac toxicity when used in combination with antihistamines such as astemizole or terfenadine, and can increase the latter's blood concentration and produce nephrotoxicity when used in combination with cyclosporine. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and is not recommended for combined use. 3. This product is an antibacterial agent that can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid antiviral effect is required, such as the treatment of meningitis, the two should not be used together. 4. Patients who have been taking warfarin for a long time may experience a prolonged prothrombin time when using erythromycin, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used together, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the combination of this product with xanthines can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of co-use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthines should be adjusted during and after the combined treatment of the two. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, its metabolism can be inhibited and blood concentrations can be increased, which may cause rhabdomyolysis. When used in combination with midazolam or triazolam, the clearance of the two can be reduced and their effects can be enhanced.